Fecal Calprotectin Levels, Quality of Life and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo
Phase of Trial: Phase IV
Latest Information Update: 03 Mar 2017
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms AdaProQuo
- Sponsors AbbVie
- 31 Aug 2018 Biomarkers information updated
- 21 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 04 Nov 2015 Planned End Date changed from 1 Aug 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.